These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33100099)

  • 1. Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study.
    Pourzardosht N; Hashemi ZS; Mard-Soltani M; Jahangiri A; Rahbar MR; Zakeri A; Mirzajani E; Khalili S
    J Recept Signal Transduct Res; 2022 Feb; 42(1):34-42. PubMed ID: 33100099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products.
    Luo L; Zhong A; Wang Q; Zheng T
    Mar Drugs; 2021 Dec; 20(1):. PubMed ID: 35049884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a PD1/PD-L1 inhibitor by structure-based pharmacophore modelling, virtual screening, molecular docking and biological evaluation.
    Choorakottayil Pushkaran A; K K; T AM; Biswas R; Mohan CG
    Mol Inform; 2023 Jun; 42(6):e2200254. PubMed ID: 36897739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.
    Waqas M; Halim SA; Alsalman A; Khan A; Elkord E; Al-Harrasi A
    J Biomol Struct Dyn; 2023; 41(24):14771-14785. PubMed ID: 36927289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
    Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
    Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction.
    Fattakhova E; Hofer J; DiFlumeri J; Cobb M; Dando T; Romisher Z; Wellington J; Oravic M; Radnoff M; Patil SP
    ChemMedChem; 2021 Sep; 16(18):2769-2774. PubMed ID: 34117723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
    Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
    Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PD1:PD-L1 interaction by an E. coli-derived optimized PD1 variant.
    Brand Shwartz M; Assor M; Dotan N; Ratzon E; Cohen E; Ruimi N; Bloch I; Gal M; Yadid I
    Biochem Biophys Res Commun; 2018 Nov; 506(3):731-738. PubMed ID: 30384998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
    Paciotti R; Agamennone M; Coletti C; Storchi L
    J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
    Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
    J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
    Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
    Shaabani S; Huizinga HPS; Butera R; Kouchi A; Guzik K; Magiera-Mularz K; Holak TA; Dömling A
    Expert Opin Ther Pat; 2018 Sep; 28(9):665-678. PubMed ID: 30107136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
    Khedri M; Abnous K; Rafatpanah H; Ramezani M
    J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
    Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
    Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.